Atea Pharmaceuticals Completes Patient Enrollment in Phase 3 C-FORWARD Trial Evaluating Bemnifosbuvir and Ruzasvir for Treatment of Hepatitis C Virus

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 9/9/2026

1. AAPL
2. BRZE
3. TTAN
4. CHYM
5. USO
6. AEO
7. COO
8. QCOM
9. IRT
10. CHWY

Go back to Atea Pharmaceuticals Completes Patient Enrollment in Phase 3 C-FORWARD Trial Evaluating Bemnifosbuvir and Ruzasvir for Treatment of Hepatitis C Virus
(NASDAQ: AVIR) Delayed: 5.27 -0.41 (7.22%)
Previous Close $5.68    52 Week High $2.00 
Open $5.64    52 Week Low $1.15 
Day High $5.66    P/E N/A 
Day Low $5.24    EPS $0.00 
Volume 430,821